Published in Antimicrob Agents Chemother on February 05, 2007
Epidemic clonal groups of Escherichia coli as a cause of antimicrobial-resistant urinary tract infections in Canada, 2002 to 2004. Antimicrob Agents Chemother (2009) 3.79
First report of the emergence of CTX-M-type extended-spectrum beta-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system. Antimicrob Agents Chemother (2007) 2.84
The continuing challenge of ESBLs. Curr Opin Pharmacol (2007) 2.12
Absence of CTX-M enzymes but high prevalence of clones, including clone ST131, among fecal Escherichia coli isolates from healthy subjects living in the area of Paris, France. J Clin Microbiol (2008) 2.06
The role of epidemic resistance plasmids and international high-risk clones in the spread of multidrug-resistant Enterobacteriaceae. Clin Microbiol Rev (2015) 2.06
Molecular characteristics of extended-spectrum-beta-lactamase-producing Escherichia coli isolates causing bacteremia in the Calgary Health Region from 2000 to 2007: emergence of clone ST131 as a cause of community-acquired infections. Antimicrob Agents Chemother (2009) 1.91
Molecular epidemiology over an 11-year period (2000 to 2010) of extended-spectrum β-lactamase-producing Escherichia coli causing bacteremia in a centralized Canadian region. J Clin Microbiol (2011) 1.67
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. Antimicrob Agents Chemother (2008) 1.66
Characteristics of NDM-1-producing Escherichia coli isolates that belong to the successful and virulent clone ST131. Antimicrob Agents Chemother (2011) 1.63
Clonal composition and community clustering of drug-susceptible and -resistant Escherichia coli isolates from bloodstream infections. Antimicrob Agents Chemother (2012) 1.60
Global fluoroquinolone resistance epidemiology and implictions for clinical use. Interdiscip Perspect Infect Dis (2012) 1.55
Clinical and molecular characteristics of extended-spectrum-beta-lactamase-producing Escherichia coli causing bacteremia in the Rotterdam Area, Netherlands. Antimicrob Agents Chemother (2011) 1.52
High prevalence of ST131 isolates producing CTX-M-15 and CTX-M-14 among extended-spectrum-beta-lactamase-producing Escherichia coli isolates from Canada. Antimicrob Agents Chemother (2010) 1.50
Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008). Antimicrob Agents Chemother (2010) 1.46
Using a commercial DiversiLab semiautomated repetitive sequence-based PCR typing technique for identification of Escherichia coli clone ST131 producing CTX-M-15. J Clin Microbiol (2009) 1.40
New Delhi metallo-beta-lactamase from traveler returning to Canada. Emerg Infect Dis (2011) 1.34
CTX-M beta-lactamases in Escherichia coli from community-acquired urinary tract infections, Cambodia. Emerg Infect Dis (2009) 1.32
Molecular characteristics of travel-related extended-spectrum-beta-lactamase-producing Escherichia coli isolates from the Calgary Health Region. Antimicrob Agents Chemother (2009) 1.26
Susceptibility of extended-spectrum-beta-lactamase-producing Enterobacteriaceae according to the new CLSI breakpoints. J Clin Microbiol (2011) 1.17
Comparison of antimicrobial resistance profiles among extended-spectrum-beta-lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care units. Antimicrob Agents Chemother (2008) 1.15
Characteristics of Escherichia coli sequence type 131 isolates that produce extended-spectrum β-lactamases: global distribution of the H30-Rx sublineage. Antimicrob Agents Chemother (2014) 1.12
Molecular epidemiology of extended-spectrum β-lactamase-producing Escherichia coli in the community and hospital in Korea: emergence of ST131 producing CTX-M-15. BMC Infect Dis (2012) 1.06
Multiresistant uropathogenic Escherichia coli from a region in India where urinary tract infections are endemic: genotypic and phenotypic characteristics of sequence type 131 isolates of the CTX-M-15 extended-spectrum-β-lactamase-producing lineage. Antimicrob Agents Chemother (2012) 1.01
Widespread dissemination of CTX-M-15 genotype extended-spectrum-β-lactamase-producing enterobacteriaceae among patients presenting to community hospitals in the southeastern United States. Antimicrob Agents Chemother (2013) 1.00
Oral and parenteral therapeutic options for outpatient urinary infections caused by enterobacteriaceae producing CTX-M extended-spectrum beta-lactamases. Antimicrob Agents Chemother (2009) 0.98
Gram-negative bacteria that produce carbapenemases causing death attributed to recent foreign hospitalization. Antimicrob Agents Chemother (2013) 0.98
Fluoroquinolone-resistant Escherichia coli sequence type 131 isolates causing bloodstream infections in a canadian region with a centralized laboratory system: rapid emergence of the H30-Rx sublineage. Antimicrob Agents Chemother (2014) 0.95
Characterization of methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci and extended-spectrum beta-lactamase-producing Escherichia coli in intensive care units in Canada: Results of the Canadian National Intensive Care Unit (CAN-ICU) study (2005-2006). Can J Infect Dis Med Microbiol (2008) 0.92
Changing epidemiology of infections due to extended spectrum beta-lactamase producing bacteria. Antimicrob Resist Infect Control (2014) 0.88
Prevalence and characterization of genotypic diversity of Haemophilus parasuis isolates from southern China. Can J Vet Res (2012) 0.87
Molecular characteristics of extended-spectrum β-lactamases in clinical isolates from Escherichia coli at a Japanese tertiary hospital. PLoS One (2013) 0.86
Molecular Evolution of a Klebsiella pneumoniae ST278 Isolate Harboring blaNDM-7 and Involved in Nosocomial Transmission. J Infect Dis (2016) 0.85
Clinical outcome of empiric antimicrobial therapy of bacteremia due to extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae. BMC Res Notes (2010) 0.85
Recent changes in the epidemiology and management of extended-spectrum β-lactamase-producing Enterobacteriaceae. F1000 Med Rep (2009) 0.80
The Widespread Presence of a Multidrug-Resistant Escherichia coli ST131 Clade among Community-Associated and Hospitalized Patients. PLoS One (2016) 0.75
Extended-Spectrum-Cephalosporin Resistance Genes in Escherichia coli from Beef Cattle. Antimicrob Agents Chemother (2015) 0.75
Evaluation of CTX-M steady-state mRNA, mRNA half-life and protein production in various STs of Escherichia coli. J Antimicrob Chemother (2015) 0.75
Possibility of CTX-M-14 Gene Transfer from Shigella sonnei to a Commensal Escherichia coli Strain of the Gastroenteritis Microbiome. Osong Public Health Res Perspect (2014) 0.75
Antibiotic Resistance and Virulence Phenotypes of Recent Bacterial Strains Isolated from Urinary Tract Infections in Elderly Patients with Prostatic Disease. Pathogens (2017) 0.75
Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol (1995) 88.05
Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev (2005) 15.72
Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes. Antimicrob Agents Chemother (2004) 10.64
PulseNet: the molecular subtyping network for foodborne bacterial disease surveillance, United States. Emerg Infect Dis (2001) 9.96
The CTX-M beta-lactamase pandemic. Curr Opin Microbiol (2006) 8.08
Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. J Antimicrob Chemother (2005) 4.87
Establishment of a universal size standard strain for use with the PulseNet standardized pulsed-field gel electrophoresis protocols: converting the national databases to the new size standard. J Clin Microbiol (2005) 4.81
Complete nucleotide sequence of a 92-kilobase plasmid harboring the CTX-M-15 extended-spectrum beta-lactamase involved in an outbreak in long-term-care facilities in Toronto, Canada. Antimicrob Agents Chemother (2004) 4.46
beta-Lactamases responsible for resistance to expanded-spectrum cephalosporins in Klebsiella pneumoniae, Escherichia coli, and Proteus mirabilis isolates recovered in South Africa. Antimicrob Agents Chemother (1998) 3.76
Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum beta-lactamases in the UK. J Antimicrob Chemother (2004) 3.69
Bacterial resistance: origins, epidemiology, and impact. Clin Infect Dis (2003) 3.42
Phenotypic and molecular detection of CTX-M-beta-lactamases produced by Escherichia coli and Klebsiella spp. J Clin Microbiol (2004) 2.95
Ambler class A extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. in Canadian hospitals. Antimicrob Agents Chemother (2004) 2.36
Effect of D240G substitution in a novel ESBL CTX-M-27. J Antimicrob Chemother (2003) 2.16
Diversity of genetic environment of bla(CTX-M) genes. FEMS Microbiol Lett (2004) 2.11
Resistance of strains producing extended-spectrum beta-lactamases and genotype distribution in China. J Infect (2006) 1.96
Population-based laboratory surveillance for Escherichia coli-producing extended-spectrum beta-lactamases: importance of community isolates with blaCTX-M genes. Clin Infect Dis (2004) 1.88
Spread of Escherichia coli strains with high-level cefotaxime and ceftazidime resistance between the community, long-term care facilities, and hospital institutions. J Clin Microbiol (2006) 1.85
Population-based epidemiological study of infections caused by carbapenem-resistant Pseudomonas aeruginosa in the Calgary Health Region: importance of metallo-beta-lactamase (MBL)-producing strains. J Infect Dis (2005) 1.80
Community-wide outbreaks of clonally related CTX-M-14 beta-lactamase-producing Escherichia coli strains in the Calgary health region. J Clin Microbiol (2005) 1.76
Unusual Salmonella enterica serotype Typhimurium isolate producing CMY-7, SHV-9 and OXA-30 beta-lactamases. J Antimicrob Chemother (2002) 1.66
CTX-M-type extended-spectrum beta-lactamases in Italy: molecular epidemiology of an emerging countrywide problem. Antimicrob Agents Chemother (2006) 1.60
Detection and characterization of extended-spectrum beta-lactamases among bloodstream isolates of Enterobacter spp. in Hong Kong, 2000-2002. J Antimicrob Chemother (2005) 1.48
What's new in antibiotic resistance? Focus on beta-lactamases. Drug Resist Updat (2006) 1.41
Development and clinical validation of a molecular diagnostic assay to detect CTX-M-type beta-lactamases in Enterobacteriaceae. Clin Microbiol Infect (2007) 1.36
Effects of restructuring on the performance of microbiology laboratories in Alberta. Arch Pathol Lab Med (2000) 1.26
Nosocomial outbreak caused by Salmonella enterica serotype Livingstone producing CTX-M-27 extended-spectrum beta-lactamase in a neonatal unit in Sousse, Tunisia. J Clin Microbiol (2005) 1.24
Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli. Diagn Microbiol Infect Dis (2006) 0.98
Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis (2008) 10.14
The comprehensive antibiotic resistance database. Antimicrob Agents Chemother (2013) 6.41
Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. J Antimicrob Chemother (2005) 4.87
A systematic evaluation of the quality of meta-analyses in the critical care literature. Crit Care (2005) 4.51
Complete nucleotide sequence of a 92-kilobase plasmid harboring the CTX-M-15 extended-spectrum beta-lactamase involved in an outbreak in long-term-care facilities in Toronto, Canada. Antimicrob Agents Chemother (2004) 4.46
Prognosis for long-term survival and renal recovery in critically ill patients with severe acute renal failure: a population-based study. Crit Care (2005) 3.96
Characterization of variant Salmonella genomic island 1 multidrug resistance regions from serovars Typhimurium DT104 and Agona. Antimicrob Agents Chemother (2002) 3.02
Occurrence and outcome of fever in critically ill adults. Crit Care Med (2008) 2.90
Detection of Pseudomonas aeruginosa producing metallo-beta-lactamases in a large centralized laboratory. J Clin Microbiol (2005) 2.89
Rapid detection of the O25b-ST131 clone of Escherichia coli encompassing the CTX-M-15-producing strains. J Antimicrob Chemother (2009) 2.85
Evaluation of the Carba NP test for rapid detection of carbapenemase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother (2013) 2.73
New quadriplex PCR assay for detection of methicillin and mupirocin resistance and simultaneous discrimination of Staphylococcus aureus from coagulase-negative staphylococci. J Clin Microbiol (2004) 2.64
Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Clin Infect Dis (2009) 2.63
Laboratory characterization of methicillin-resistant Staphylococcus aureus in Canadian hospitals: results of 5 years of National Surveillance, 1995-1999. J Infect Dis (2002) 2.57
Population-based study of the epidemiology of and the risk factors for pyogenic liver abscess. Clin Gastroenterol Hepatol (2004) 2.44
Severe bloodstream infections: a population-based assessment. Crit Care Med (2004) 2.39
The Salmonella genomic island 1 is an integrative mobilizable element. Mol Microbiol (2005) 2.29
Laboratory detection of Enterobacteriaceae that produce carbapenemases. J Clin Microbiol (2012) 2.24
Staphylococcus aureus bloodstream infections: risk factors, outcomes, and the influence of methicillin resistance in Calgary, Canada, 2000-2006. J Infect Dis (2008) 2.21
Accuracy of Peripheral Thermometers for Estimating Temperature: A Systematic Review and Meta-analysis. Ann Intern Med (2015) 2.19
CKD and risk of hospitalization and death with pneumonia. Am J Kidney Dis (2009) 2.17
Community-onset extended-spectrum beta-lactamase (ESBL) producing Escherichia coli: importance of international travel. J Infect (2008) 2.11
Chest tube complications: how well are we training our residents? Can J Surg (2007) 2.08
Population-based study of the epidemiology of and the risk factors for invasive Staphylococcus aureus infections. J Infect Dis (2003) 2.00
Is regional citrate superior to systemic heparin anticoagulation for continuous renal replacement therapy? A prospective observational study in an adult regional critical care system. J Crit Care (2005) 2.00
Non-neurologic organ dysfunction in severe traumatic brain injury. Crit Care Med (2005) 1.95
Molecular characteristics of extended-spectrum-beta-lactamase-producing Escherichia coli isolates causing bacteremia in the Calgary Health Region from 2000 to 2007: emergence of clone ST131 as a cause of community-acquired infections. Antimicrob Agents Chemother (2009) 1.91
Limited ability of SOFA and MOD scores to discriminate outcome: a prospective evaluation in 1,436 patients. Can J Anaesth (2005) 1.90
Population-based laboratory surveillance for Escherichia coli-producing extended-spectrum beta-lactamases: importance of community isolates with blaCTX-M genes. Clin Infect Dis (2004) 1.88
A population-based study of pyogenic liver abscesses in the United States: incidence, mortality, and temporal trends. Am J Gastroenterol (2009) 1.84
Time to blood culture positivity in Staphylococcus aureus bacteremia: association with 30-day mortality. J Infect (2010) 1.84
Variant Salmonella genomic island 1 antibiotic resistance gene cluster in Salmonella enterica serovar Albany. Emerg Infect Dis (2003) 1.84
Surveillance and molecular epidemiology of Klebsiella pneumoniae isolates that produce carbapenemases: first report of OXA-48-like enzymes in North America. Antimicrob Agents Chemother (2012) 1.83
Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J Antimicrob Chemother (2007) 1.82
Population-based epidemiological study of infections caused by carbapenem-resistant Pseudomonas aeruginosa in the Calgary Health Region: importance of metallo-beta-lactamase (MBL)-producing strains. J Infect Dis (2005) 1.80
Needle thoracostomy in the treatment of a tension pneumothorax in trauma patients: what size needle? J Trauma (2008) 1.76
Community-wide outbreaks of clonally related CTX-M-14 beta-lactamase-producing Escherichia coli strains in the Calgary health region. J Clin Microbiol (2005) 1.76
Development and validation of a molecular beacon probe-based real-time polymerase chain reaction assay for rapid detection of methicillin resistance in Staphylococcus aureus. Arch Pathol Lab Med (2003) 1.74
New Delhi metallo-β-lactamase-1: local acquisition in Ontario, Canada, and challenges in detection. CMAJ (2011) 1.73
AcrAB-TolC directs efflux-mediated multidrug resistance in Salmonella enterica serovar typhimurium DT104. Antimicrob Agents Chemother (2004) 1.73
Salmonella enterica serotype Typhimurium DT 104 antibiotic resistance genomic island I in serotype paratyphi B. Emerg Infect Dis (2002) 1.73
Molecular epidemiology over an 11-year period (2000 to 2010) of extended-spectrum β-lactamase-producing Escherichia coli causing bacteremia in a centralized Canadian region. J Clin Microbiol (2011) 1.67
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. Antimicrob Agents Chemother (2008) 1.66
Renal arterial resistive index response to intraabdominal hypertension in a porcine model. Crit Care Med (2007) 1.65
Salmonella resistant to extended-spectrum cephalosporins: prevalence and epidemiology. Microbes Infect (2006) 1.64
One-year mortality in critically ill patients by severity of kidney dysfunction: a population-based assessment. Am J Kidney Dis (2006) 1.62
Development of a triplex real-time PCR assay for detection of Panton-Valentine leukocidin toxin genes in clinical isolates of methicillin-resistant Staphylococcus aureus. J Clin Microbiol (2005) 1.56
Population-based laboratory surveillance for AmpC beta-lactamase-producing Escherichia coli, Calgary. Emerg Infect Dis (2007) 1.56
Incidence, risk factors, and outcomes of Klebsiella pneumoniae bacteremia. Am J Med (2009) 1.56
Colonization of returning travelers with CTX-M-producing Escherichia coli. J Travel Med (2011) 1.53
Identification of a progenitor of the CTX-M-9 group of extended-spectrum beta-lactamases from Kluyvera georgiana isolated in Guyana. Antimicrob Agents Chemother (2005) 1.50
Comparative genomics of Canadian epidemic lineages of methicillin-resistant Staphylococcus aureus. J Clin Microbiol (2007) 1.49
Virulence factors of Escherichia coli isolates that produce CTX-M-type extended-spectrum beta-lactamases. Antimicrob Agents Chemother (2005) 1.49
Surveillance for certain health behaviors among states and selected local areas--behavioral risk factor surveillance system, United States, 2004. MMWR Surveill Summ (2006) 1.49
Molecular methods for pathogen and microbial community detection and characterization: current and potential application in diagnostic microbiology. Infect Genet Evol (2012) 1.48
Fever in adult ICUs: an interrupted time series analysis*. Crit Care Med (2013) 1.47
Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008). Antimicrob Agents Chemother (2010) 1.46
Invasive Candida species infections: a 5 year population-based assessment. J Antimicrob Chemother (2005) 1.43
Clinical usefulness of components of the Triage immunoassay, enzyme immunoassay for toxins A and B, and cytotoxin B tissue culture assay for the diagnosis of Clostridium difficile diarrhea. Am J Clin Pathol (2003) 1.42
Use of near-infrared spectroscopy as a physiologic monitor for intra-abdominal hypertension. J Trauma (2008) 1.41
Livestock-associated methicillin-resistant Staphylococcus aureus sequence type 398 in humans, Canada. Emerg Infect Dis (2010) 1.41
Using a commercial DiversiLab semiautomated repetitive sequence-based PCR typing technique for identification of Escherichia coli clone ST131 producing CTX-M-15. J Clin Microbiol (2009) 1.40
Molecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11. J Antimicrob Chemother (2013) 1.39
Factors related to the failure of radiographic recognition of occult posttraumatic pneumothoraces. Am J Surg (2005) 1.39
Surveillance for plasmid-mediated quinolone resistance determinants in Enterobacteriaceae within the Calgary Health Region, Canada: the emergence of aac(6')-Ib-cr. J Antimicrob Chemother (2008) 1.38
Methicillin-resistant Staphylococcus aureus colonization or infection in Canada: National Surveillance and Changing Epidemiology, 1995-2007. Infect Control Hosp Epidemiol (2010) 1.35
Salmonella genomic island 1 multidrug resistance gene clusters in Salmonella enterica serovar Agona isolated in Belgium in 1992 to 2002. Antimicrob Agents Chemother (2004) 1.33
A preliminary guideline for the assignment of methicillin-resistant Staphylococcus aureus to a Canadian pulsed-field gel electrophoresis epidemic type using spa typing. Can J Infect Dis Med Microbiol (2008) 1.32
Enterococcus faecium N03-0072 carries a new VanD-type vancomycin resistance determinant: characterization of the VanD5 operon. J Antimicrob Chemother (2004) 1.31
Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa in the Calgary Health Region: emergence of VIM-2-producing isolates. J Clin Microbiol (2006) 1.31
Occurrence and adverse effect on outcome of hyperlactatemia in the critically ill. Crit Care (2009) 1.31
Molecular epidemiology of extended-spectrum-β-lactamase-producing Klebsiella pneumoniae over a 10 year period in Calgary, Canada. J Antimicrob Chemother (2012) 1.29
Molecular characterization of Enterococcus faecalis N06-0364 with low-level vancomycin resistance harboring a novel D-Ala-D-Ser gene cluster, vanL. Antimicrob Agents Chemother (2008) 1.29
Antipyretic therapy in febrile critically ill adults: A systematic review and meta-analysis. J Crit Care (2012) 1.26
VanG-type vancomycin-resistant Enterococcus faecalis strains isolated in Canada. Antimicrob Agents Chemother (2006) 1.26